Can MRI predict the histopathological response in patients with osteosarcoma after the first cycle of chemotherapy?

doi:10.1016/S0009-9260(05)83135-6

Clinical Radiology

Volume 50, Issue 6, June 1995, Pages 384-390

https://doi.org/10.1016/S0009-9260(05)83135-6 Get rights and content

The magnetic resonance (MR) changes after one cycle of chemotherapy were compared with the prechemotherapy studies in 39 patients with osteosarcoma, in order to identify MR changes which can be used to assess early response to chemotherapy. Measurements of total tumour volume, signal intensity, and tumour enhancement of the intra- and extraosseous tumour component were performed. Change in the amount of oedema was subjectively assessed. Changes observed were correlated with histopathological response.

Changes in tumour volume and of the signal intensity of the extraosseous tumour component on T2-weighting were the only two parameters which correlated significantly (P<0.05) with histopathological response. Increase of tumour volume is the most significant parameter and indicates poor response (sensitivity 89%, specificity 73%). Only one good responder showed increase of tumour volume. Decreased or stable tumour volume was observed in both good and poor responders. Increase of signal intensity was found exclusively in five poor responders (sensitivity 100%, specificity 23%). Decreased or stable signal intensity was observed in both good and poor responders. Changes in the amount of oedema and contrast enhancement could not predict response at an early stage.

We conclude that increase of tumour volume and increase of T2 signal intensity of extraosseous tumour can be predictive for poor response. MR criteria are not helpful in the early identification of good responders.

References (32)

GlasserDB et al.
Survival, prognosis, and therapeutic response in osteogenic sarcoma
Cancer
(1992)
MeyersPA et al.
Chemotherapy for non-metastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience
Journal of Clinical Oncology
(1992)
RaymondAK et al.
Osteosarcoma chemotherapy effect: a prognostic factor
Seminars in Diagnostic Pathology
(1987)
WinklerK et al.
Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study
Journal of Clinical Oncology
(1984)
de BaereT et al.
Osteosarcoma after chemotherapy: evaluation with contrast material-enhanced subtraction MR imaging
Radiology
(1992)
ErlemannR et al.
Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy
Radiology
(1990)
FletcherBD
Response of osteosarcoma and Ewing sarcoma to chemotherapy: imaging evaluation
American Journal of Roentgenology
(1991)
FletcherBD et al.
Pediatric musculoskeletal tumors: use of dynamic contrast-enhanced MR imaging to monitor response to chemotherapy
Radiology
(1992)
HannaSL et al.
Assessment of osteosarcoma response to preoperative chemotherapy using dynamic FLASH Gadolinium-DTPA-enhanced magnetic resonance imaging
Investigative Radiology
(1992)
HolscherHC et al.
The value of MR imaging in monitoring the effect of chemotherapy on bone sarcomas
American Journal of Roentgenology
(1990)

HolscherHC et al.

Osteosarcoma: chemotherapy-induced changes at MR imaging

Radiology

(1992)

LawrenceJA et al.

Extremity osteosarcoma in childhood: prognostic value of radiologic imaging

Radiology

(1993)

MaasR et al.

The potential of MRI in preoperative evaluation of chemotherapy-induced necrosis in osteosarcoma and Ewing's sarcoma

Chirurgia Degli Organi di Movimento

(1990)

PanG et al.

Osteosarcoma: MR imaging after preoperative chemotherapy

Radiology

(1990)

RedmondOM et al.

Osteosarcoma: use of MR imaging and MR spectroscopy in clinical decision making

Radiology

(1989)

BonnerotV et al.

Factor analysis of dynamic magnetic resonance imaging in predicting the response of osteosarcoma to chemotherapy

Investigative Radiology

(1992)

Cited by (50)

Inter-rater Variability in the Interpretation of Pre and Post Contrast MRI for Pre-Surgical Evaluation of Osteosarcoma in Long Bones in Pediatric Patients and Young Adults
2019, Surgical Oncology
Citation Excerpt :
Furthermore, for our purposes we believe that the pathology results are only truly of interest in the cases in which pre contrast only and pre and post contrast image interpretations were found to be discordant. The assessment of pathology results for other cases would address overall MRI performance, however this has been well assessed in the literature by multiple previous authors [9, 16, 17, 19, 22, 28]. We acknowledge that many surgeons and radiologists may prefer utilizing gadolinium, particularly for oncologic purposes, since this has been common practice for decades.
The value of gadolinium enhanced magnetic resonance imaging (MRI) sequences for extremity osteosarcoma resection planning is unverified. We evaluate the performance of intravenous gadolinium enhanced MRI for identification of neurovascular bundle involvement (NBI) and intraarticular extension (IAE) in patients with osteosarcoma.
Two pediatric radiologists independently analyzed MRI examinations of patients with pathology proven extremity osteosarcoma for NBI and IAE. Initial evaluation utilized only non-contrast MRI images (PRE) and, after 2 weeks, subsequent evaluation included both the pre and post contrast images (POST). Cohen’s Kappa and McNemar’s test were calculated to assess agreement between PRE and POST image interpretations of NBI and IAE.
56 patients with 90 preoperative MRI examinations were analyzed. PRE and POST interpretations were rarely discordant; 4/90 cases for NBI (Kappa 0.91) and 2/90 cases for IAE (Kappa 0.95). McNemar’s test did not show a difference between PRE and POST imaging (NBI p=0.62; IAE p=0.48).
No significant difference between PRE and POST image interpretation was found. A high level of agreement between PRE and POST image interpretation suggests that pre-contrast MRI may be sufficient for pre-surgical planning for pediatric patients with long bone osteosarcoma.
The significance of size change of soft tissue sarcoma during preoperative radiotherapy
2010, European Journal of Surgical Oncology
Citation Excerpt :
Tumour shrinkage and decreasing signal intensity on MRI in cervical carcinoma indicates a good response.13–15 In osteosarcoma, several studies have demonstrated the correlation between decrease in tumour size on MRI and pathologic response in patients treated with neoadjuvant chemotherapy.16–18 These studies report that increasing in tumour size correlates with a poor histological response, and conclude that change in tumour volume is an independent prognostic factor.
To assess the significance of change in tumour size during preoperative radiotherapy in patients with soft tissue sarcoma (STS).
A retrospective review of 91 cases with STS was performed. Inclusion criteria were localised extremity and truncal STS with measurable disease, older than 18 years, treated with preoperative radiotherapy and wide local excision, in the period between January 1966 and December 2005. Patients with head and neck STS, or who received neoadjuvant chemotherapy were excluded. A difference in excess of 10% of the greatest tumour diameter of the pre-radiotherapy and the post-radiotherapy MRI scans was considered as change in tumour size.
Increase in tumour size was noted in 28 patients (31%) (Group 1). No change or decrease in size was observed in 63 patients (Group 2). There were no significance differences in local control or overall survival rates between the 2 groups. The estimated overall actuarial local recurrence free, event-free and overall survival rates were 90.5%, 64.4%, 62.9% in Group 1, and 85.7%, 60.8%, 68.9% in Group 2 respectively.
Increase in tumour size during preoperative radiotherapy for soft tissue sarcoma does not seem to associate with inferior local tumour control or compromise survival. Lack of reduction in tumour size is not necessarily a sign of lack of response to preoperative radiotherapy.
Diffusion-Weighted MR Imaging in Musculoskeletal Radiology: Applications in Trauma, Tumors, and Inflammation
2009, Magnetic Resonance Imaging Clinics of North America
Citation Excerpt :
Furthermore, this method is invasive and unfavorable as a means of routine follow-up examinations. Conventional MR criteria may not be helpful in the early identification of good responders, and nested foci of residual viable tumor may be overseen.38,39 Instead, detection of necrosis has been recognized as a prognostic factor of tumor response to chemotherapy in Ewing sarcoma and osteogenic sarcoma.40
Diffusion-weighted imaging is a noninvasive magnetic resonance technique that is capable of measuring icroscopic movement of water molecules (ie, random or Brownian motion) within biologic tissues. Diffusion weighting is achieved with a pulsed-field gradient that leaves “static” spins unaffected but causes dephasing of spin ensembles that experience different motion histories according to their diffusion paths, with respect to the direction of the gradient. This article focuses on the interesting opportunities of the use of diffusion weighted imaging in the diagnosis of musculoskeletal diseases, including trauma, tumor, and inflammation.
Effect of increases in tumor volume after neoadjuvant chemotherapy on the outcome of stage II osteosarcoma regardless of histological response
2009, Journal of Orthopaedic Science
We assessed volume changes after neoadjuvant chemotherapy and evaluated relations between tumor size changes and clinical characteristics. In addition, we sought to determine whether tumor size change influences patient outcome.
The records of 127 patients with stage II osteosarcoma who showed more than a 15% volume change after chemotherapy were retrospectively reviewed. Patients were divided into two groups depending on whether tumors increased or decreased in size. Fisher’s exact test was performed to analyze correlations between tumor size changes and clinicopathological variables. Five-year metastasis-free survival and overall survival were evaluated using univariate and multivariate analyses.
A total of 71 patients (55.9%) showed a decrease in tumor volume, and 56 patients (44.1%) showed an increase. An increase in tumor volume after neoadjuvant chemotherapy was found to be positively correlated with a poor histological response and subsequent metastasis. Univariate analysis identified the following parameters as poor prognostic factors: age < 15 years (P = 0.03), American Joint Committee on Cancer (AJCC) stage IIB (p = 0.02), a subtype other than osteoblastic (P < 0.01), a poor histological response (P < 0.001), and increased tumor volume after preoperative chemotherapy (P < 0.0001). Multivariate analysis revealed that AJCC stage IIB (P = 0.006) and an increase in tumor volume after preoperative chemotherapy (P < 0.001) both independently shortened metastasis-free survival. However, a poor histological response lost its prognostic significance (P = 0.34).
Increased tumor volume after neoadjuvant chemotherapy independently shortened metastasis-free and overall survival in AJCC stage II osteosarcoma patients. Tumor volume changes may serve as a basis for risk-adapted therapy when used in combination with other prognostic factors.
Evaluation of response to neoadjuvant chemotherapy in osteosarcoma using dynamic contrast-enhanced MRI: development and external validation of a model
2024, Skeletal Radiology
Mediating effect assessment of ifosfamide on limb salvage rate in osteosarcoma: A study from a single center in China
2022, Frontiers in Oncology

View all citing articles on Scopus

View full text

Can MRI predict the histopathological response in patients with osteosarcoma after the first cycle of chemotherapy?

Survival, prognosis, and therapeutic response in osteogenic sarcoma

Cancer

Chemotherapy for non-metastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience

Journal of Clinical Oncology

Osteosarcoma chemotherapy effect: a prognostic factor

Seminars in Diagnostic Pathology

Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study

Journal of Clinical Oncology

Osteosarcoma after chemotherapy: evaluation with contrast material-enhanced subtraction MR imaging

Radiology

Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy

Radiology

Response of osteosarcoma and Ewing sarcoma to chemotherapy: imaging evaluation

American Journal of Roentgenology

Pediatric musculoskeletal tumors: use of dynamic contrast-enhanced MR imaging to monitor response to chemotherapy

Radiology

Assessment of osteosarcoma response to preoperative chemotherapy using dynamic FLASH Gadolinium-DTPA-enhanced magnetic resonance imaging

Investigative Radiology

The value of MR imaging in monitoring the effect of chemotherapy on bone sarcomas

American Journal of Roentgenology

Osteosarcoma: chemotherapy-induced changes at MR imaging

Radiology

Extremity osteosarcoma in childhood: prognostic value of radiologic imaging

Radiology

The potential of MRI in preoperative evaluation of chemotherapy-induced necrosis in osteosarcoma and Ewing's sarcoma

Chirurgia Degli Organi di Movimento

Osteosarcoma: MR imaging after preoperative chemotherapy

Radiology

Osteosarcoma: use of MR imaging and MR spectroscopy in clinical decision making

Radiology

Factor analysis of dynamic magnetic resonance imaging in predicting the response of osteosarcoma to chemotherapy

Investigative Radiology